Literature DB >> 29129562

Preoperative Use of Oral Beta-Adrenergic Blocking Agents and the Incidence of New-Onset Atrial Fibrillation After Cardiac Surgery. A Systematic Review and Meta-Analysis.

Paul Min Thein1, Kyle White2, Khyati Banker2, Carole Lunny3, Sam Mirzaee4, Arthur Nasis4.   

Abstract

BACKGROUND: Current epidemiological data suggests that postoperative atrial fibrillation or atrial flutter (POAF) causes significant morbidity and mortality after cardiac surgery. The literature for prophylactic management of POAF is limited, resulting in the lack of clear guidelines on management recommendations. AIM: To examine the efficacy of prophylactic rate control agents in reducing the incidence of new-onset POAF in patients undergoing elective cardiac surgery.
METHODS: Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Medline were systematically searched for blinded randomised controlled studies (RCT) evaluating adults with no history of atrial fibrillation randomised to a pharmacological agent (either beta blocker, calcium channel blocker or digoxin), compared to placebo. Utilising Cochrane guidance, three reviewers screened, extracted and the quality of the evidence was assessed. We used a random effects meta-analysis to compare a rate-control agent with placebo.
RESULTS: Five RCTs (688 subjects, mean age 61±8.9, 69% male) were included. Beta blocker administration prior to elective cardiac surgery significantly reduced the incidence of POAF (OR 0.43, 95%Cl [0.30-0.61], I2=0%) without significant impact on ischaemic stroke (OR 0.49, 95%Cl [0.10-2.44], I2=0%), non-fatal myocardial infarction (OR 0.76, 95%Cl [0.08-7.44], I2=0%), overall mortality (OR 0.83, 95%Cl [0.19-3.66], I2=0%), or length of stay (mean -0.96days 95%Cl [-1.49 to -0.42], I2=0%). An increased rate of bradycardic episodes was observed (OR 3.53, 95%Cl [1.22-10.23], I2=0%).
CONCLUSIONS: This review suggests that selective administration of prophylactic oral beta blockers prior to elective cardiac surgery is safe and may reduce the incidence of POAF.
Copyright © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Atrial flutter; Beta blocker; Cardiac surgery; New onset; Prophylaxis

Mesh:

Substances:

Year:  2017        PMID: 29129562     DOI: 10.1016/j.hlc.2017.08.026

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  5 in total

Review 1.  Contemporary personalized β-blocker management in the perioperative setting.

Authors:  Adriana D Oprea; Xiaoxiao Wang; Robert Sickeler; Miklos D Kertai
Journal:  J Anesth       Date:  2019-10-21       Impact factor: 2.078

Review 2.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

3.  New-Onset Atrial Fibrillation in Adult Patients After Cardiac Surgery.

Authors:  Peter S Burrage; Ying H Low; Niall G Campbell; Ben O'Brien
Journal:  Curr Anesthesiol Rep       Date:  2019-04-24

4.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-23

5.  Prevalence and risk factors of atrial fibrillation during lung and esophageal surgery: A Prospective observational study.

Authors:  Kangjie Xie; Wen Zhang; Jun Fang; Ye Guo; Man Fang; Zewu Ding; Yuqian Hu; Weifeng Yu; Fugui Li
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.